MTOR and post-transplant lymphoproliferative disease: The differential activity of these inhibitors can be explained by induction of the NFKB pathway (by LMP1), the PI3K/Akt/mTOR pathways (by LMP2A) and heat-shock proteins in EBV-positive PTLD [105].